Arcturus Therapeutics Competitors

Biohaven Pharmaceutical (NYSE:BHVN) and Arcturus Therapeutics (NASDAQ:ARCT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Biohaven Pharmaceutical and Arcturus Therapeutics' revenue, earnings per share and valuation.

Arcturus Therapeutics has higher revenue and earnings than Biohaven Pharmaceutical. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Biohaven Pharmaceutical and Arcturus Therapeutics, as provided by MarketBeat.com.

Biohaven Pharmaceutical currently has a consensus price target of $95.30, indicating a potential upside of 15.28%. Arcturus Therapeutics has a consensus price target of $70.6154, indicating a potential upside of 30.87%. Given Arcturus Therapeutics' higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Biohaven Pharmaceutical.

Profitability

This table compares Biohaven Pharmaceutical and Arcturus Therapeutics' net margins, return on equity and return on assets.

Risk and Volatility

Biohaven Pharmaceutical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Biohaven Pharmaceutical on 7 of the 13 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Arcturus Therapeutics and Sage Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Arcturus Therapeutics has higher revenue and earnings than Sage Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Arcturus Therapeutics and Sage Therapeutics, as provided by MarketBeat.com.

Arcturus Therapeutics currently has a consensus price target of $70.6154, suggesting a potential upside of 30.87%. Sage Therapeutics has a consensus price target of $80.50, suggesting a potential downside of 4.33%. Given Arcturus Therapeutics' higher probable upside, equities analysts plainly believe Arcturus Therapeutics is more favorable than Sage Therapeutics.

Profitability

This table compares Arcturus Therapeutics and Sage Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

74.3% of Arcturus Therapeutics shares are held by institutional investors. 12.6% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Arcturus Therapeutics has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Sage Therapeutics on 10 of the 14 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Eidos Therapeutics (NASDAQ:EIDX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

74.3% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 31.4% of Eidos Therapeutics shares are held by institutional investors. 12.6% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 70.1% of Eidos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Arcturus Therapeutics and Eidos Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Arcturus Therapeutics has higher earnings, but lower revenue than Eidos Therapeutics. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Arcturus Therapeutics and Eidos Therapeutics, as reported by MarketBeat.com.

Arcturus Therapeutics currently has a consensus price target of $70.6154, suggesting a potential upside of 30.87%. Eidos Therapeutics has a consensus price target of $53.4520, suggesting a potential downside of 56.26%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Arcturus Therapeutics is more favorable than Eidos Therapeutics.

Profitability

This table compares Arcturus Therapeutics and Eidos Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Arcturus Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Eidos Therapeutics has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Eidos Therapeutics on 9 of the 14 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

74.3% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 12.6% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Arcturus Therapeutics and Arena Pharmaceuticals, as reported by MarketBeat.com.

Arcturus Therapeutics presently has a consensus price target of $70.6154, suggesting a potential upside of 30.87%. Arena Pharmaceuticals has a consensus price target of $90.2143, suggesting a potential upside of 17.45%. Given Arcturus Therapeutics' higher probable upside, research analysts plainly believe Arcturus Therapeutics is more favorable than Arena Pharmaceuticals.

Profitability

This table compares Arcturus Therapeutics and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Arcturus Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Earnings & Valuation

This table compares Arcturus Therapeutics and Arena Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arena Pharmaceuticals beats Arcturus Therapeutics on 10 of the 14 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Arcturus Therapeutics (NASDAQ:ARCT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for ChemoCentryx and Arcturus Therapeutics, as provided by MarketBeat.com.

ChemoCentryx presently has a consensus target price of $80.7778, suggesting a potential upside of 20.92%. Arcturus Therapeutics has a consensus target price of $70.6154, suggesting a potential upside of 30.87%. Given Arcturus Therapeutics' higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than ChemoCentryx.

Earnings and Valuation

This table compares ChemoCentryx and Arcturus Therapeutics' revenue, earnings per share and valuation.

Arcturus Therapeutics has lower revenue, but higher earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ChemoCentryx and Arcturus Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

ChemoCentryx has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500.

Insider & Institutional Ownership

80.7% of ChemoCentryx shares are owned by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are owned by institutional investors. 9.3% of ChemoCentryx shares are owned by insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ChemoCentryx beats Arcturus Therapeutics on 10 of the 15 factors compared between the two stocks.

Reata Pharmaceuticals (NASDAQ:RETA) and Arcturus Therapeutics (NASDAQ:ARCT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Volatility & Risk

Reata Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the S&P 500.

Valuation & Earnings

This table compares Reata Pharmaceuticals and Arcturus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Arcturus Therapeutics has lower revenue, but higher earnings than Reata Pharmaceuticals. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Reata Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

64.3% of Reata Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are owned by institutional investors. 31.7% of Reata Pharmaceuticals shares are owned by company insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Reata Pharmaceuticals and Arcturus Therapeutics, as reported by MarketBeat.

Reata Pharmaceuticals currently has a consensus price target of $251.25, indicating a potential upside of 94.27%. Arcturus Therapeutics has a consensus price target of $70.6154, indicating a potential upside of 30.87%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Reata Pharmaceuticals is more favorable than Arcturus Therapeutics.

Profitability

This table compares Reata Pharmaceuticals and Arcturus Therapeutics' net margins, return on equity and return on assets.